Ford, I

Du Puy, R S; Postmus, I; Stott, D J; Blum, Manuel; Poortvliet, R K E; Den Elzen, W P J; Peeters, R P; van Munster, B C; Wolffenbuttel, B H R; Westendorp, R G J; Kearney, P M; Ford, I; Kean, S; Messow, C M; Watt, T; Jukema, J W; Dekkers, O M; Smit, J W A; Rodondi, Nicolas; Gussekloo, J; ... (2018). Study protocol: a randomised controlled trial on the clinical effects of levothyroxine treatment for subclinical hypothyroidism in people aged 80 years and over. BMC Endocrine Disorders, 18(1), p. 67. BioMed Central 10.1186/s12902-018-0285-8

Bousser, M G; Amarenco, P; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, H P; Rothwell, P M (2009). The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovascular diseases, 27(6), pp. 608-13. Basel: Karger 10.1159/000216835

Bousser, M G; Amarenco, P; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M G; Mattle, H P; Rothwell, P M (2009). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular diseases, 27(5), pp. 509-18. Basel: Karger 10.1159/000212671